Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Aged
Aged, 80 and over
Dose-Response Relationship, Drug
Female
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Male
Melphalan
/ administration & dosage
Middle Aged
Multiple Myeloma
/ mortality
Neoplasm Recurrence, Local
/ pathology
Progression-Free Survival
Transplantation, Autologous
/ methods
Treatment Outcome
United States
age
geriatric oncology
myeloma
transplantation
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
20
04
2020
revised:
26
05
2020
accepted:
17
06
2020
pubmed:
24
9
2020
medline:
28
5
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori. An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m The results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
Sections du résumé
BACKGROUND
Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults.
METHODS
The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori.
RESULTS
An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m
CONCLUSIONS
The results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
Identifiants
pubmed: 32965680
doi: 10.1002/cncr.33171
pmc: PMC8063213
mid: NIHMS1683961
doi:
Substances chimiques
Melphalan
Q41OR9510P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5077-5087Subventions
Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : Terumo BCT
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : Novartis Oncology
Organisme : s Hospital
Organisme : Kyowa Kirin
Organisme : Public Health Service
ID : U24CA076518
Organisme : Genzyme
Organisme : Sanofi Genzyme
Organisme : NHLBI NIH HHS
ID : HHSH250201700007C
Pays : United States
Organisme : REGiMMUNE Corporation
Organisme : Pharmacyclics LLC
Organisme : bluebird bio Inc
Organisme : Anthem Inc
Organisme : National Institute of Allergy and Infectious Diseases
ID : U24HL138660
Organisme : NHLBI NIH HHS
ID : SC1MC31881-01-00
Pays : United States
Organisme : Japan Hematopoietic Cell Transplantation Data Center
Organisme : HRSA HHS
ID : N00014-20-1-2705
Pays : United States
Organisme : Janssen/Johnson & Johnson
Organisme : Mesoblast
Organisme : s Foundation
Organisme : AlloVir Inc
Organisme : HistoGenetics Inc
Organisme : Kite Pharma
Organisme : Pfizer Inc
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : Millennium
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : Janssen Biotech Inc
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL141445
Pays : United States
Organisme : Orca Biosystems Inc
Organisme : Amgen Inc
Organisme : '
Organisme : NIAID NIH HHS
ID : U01 AI069197
Pays : United States
Organisme : Actinium Pharmaceuticals Inc
Organisme : AstraZeneca
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : Adienne SA
Organisme : Kiadis Pharma
Organisme : Novartis Pharmaceuticals Corporation
Organisme : Medical College of Wisconsin
Organisme : Jazz Pharmaceuticals Inc
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : Biomedical Advanced Research and Development Authority
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Be The Match Foundation
Organisme : Incyte Corporation
Organisme : Regeneron Pharmaceuticals Inc
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States
Organisme : Daiichi Sankyo Company Ltd
Organisme : Viracor Eurofins
Organisme : Merck & Company Inc
Organisme : CytoSen Therapeutics Inc
Organisme : Astellas Pharma US
Organisme : Takeda Oncology
Organisme : HRSA HHS
ID : N00014-18-1-2850
Pays : United States
Organisme : AbbVie
Organisme : Seattle Genetics
Organisme : St. Baldrick
Organisme : Gamida Cell Ltd
Organisme : OncoImmune Inc
Organisme : Adaptive Biotechnologies
Organisme : National Marrow Donor Program
Organisme : Sobi Inc
Organisme : Bristol-Myers Squibb
Organisme : HRSA HHS
ID : N00014-18-1-2888
Pays : United States
Organisme : Boston Children
Organisme : Celgene Corporation
Organisme : Dana-Farber Cancer Institute
Organisme : NHLBI NIH HHS
ID : K23HL141445 HHSH250201700006C
Pays : United States
Organisme : CSL Behring
Organisme : Medac GmbH
Organisme : GlaxoSmithKline
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : R21HL140314
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218285
Pays : United States
Organisme : Legend Biotech
Organisme : NHLBI NIH HHS
ID : R01 HL130388
Pays : United States
Organisme : NCI NIH HHS
ID : OT3HL147741
Pays : United States
Organisme : NCI NIH HHS
ID : U01HL128568
Pays : United States
Organisme : Takeda Oncology Corporation
Organisme : NCI NIH HHS
ID : R01 CA215134
Pays : United States
Organisme : Xenikos BV
Organisme : Takeda Pharma
Organisme : Chimerix Inc
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : Omeros Corporation
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : Merck Sharp & Dohme Corporation
Organisme : Miltenyi Biotec Inc
Organisme : Mallinckrodt LLC
Organisme : Atara Biotherapeutics Inc
Organisme : NIAID NIH HHS
ID : R01 AI128775
Pays : United States
Organisme : Magenta Therapeutics
Organisme : Janssen Pharmaceuticals Inc
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2020 American Cancer Society.
Références
Blood Adv. 2017 Jan 4;1(4):282-287
pubmed: 29296944
Haematologica. 2020 May;105(5):1183-1188
pubmed: 32241848
N Engl J Med. 2014 Sep 4;371(10):895-905
pubmed: 25184862
Biol Blood Marrow Transplant. 2015 Apr;21(4):701-6
pubmed: 25555447
Biol Blood Marrow Transplant. 2015 Oct;21(10):1823-9
pubmed: 26033281
Leukemia. 2017 Sep;31(9):1998-2000
pubmed: 28663578
Bone Marrow Transplant. 2016 Nov;51(11):1449-1455
pubmed: 27376447
Blood. 2019 Jun 13;133(24):2615-2618
pubmed: 31003998
Biol Blood Marrow Transplant. 2013 Nov;19(11):1615-24
pubmed: 23939198
Cancer. 2017 Aug 15;123(16):3141-3149
pubmed: 28472539
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421
pubmed: 28606646
N Engl J Med. 2017 Jul 6;377(1):93-94
pubmed: 28679088
J Clin Oncol. 2019 Mar 1;37(7):589-597
pubmed: 30653422
JAMA Oncol. 2019 Jun 3;:
pubmed: 31158272
Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172
pubmed: 28159578
Lancet Oncol. 2015 Dec;16(16):1617-29
pubmed: 26596670
Leuk Lymphoma. 2016 Dec;57(12):2827-2832
pubmed: 27104965